Mga Batayang Estadistika
| LEI | 529900E3KUAEG4GJ1707 |
| CIK | 1019695 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ArQule, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARQULE INC (Name of Issuer) (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Ru |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARQULE INC (Name of Issuer) (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Ru |
|
| February 14, 2020 |
SC 13G 1 arql21420.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARQULE INC (Name of Issuer) (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 9)1 ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, |
|
| February 14, 2020 |
Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the common stock, par value $0.01 per share, of ArQule, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)( |
|
| February 12, 2020 |
ARQL / ArQule, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ARQULE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 04269E107 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuan |
|
| February 12, 2020 |
ARQL / ArQule, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: ArQule Inc Title of Class of Securities: Common Stock CUSIP Number: 04269E107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 10, 2020 |
ARQL / ArQule, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ArQule, Inc. (Name of Issuer) Common Stock, par value $.01 (Title of Class of Securities) 04269E107 (CUSIP Number) January 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 27, 2020 |
ARQL / ArQule, Inc. 15-12G - - 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 000-21429 ArQule, Inc. (Exact name of registrant as specified in its charter) O |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Numbe |
|
| January 16, 2020 |
ARQL / ArQule, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
8-K 1 tm203495d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2020 ArQule, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21429 04-3221586 (State or other Jurisdiction of Inco |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
Merck Completes Acquisition of ArQule Exhibit (a)(5)(A) News Release FOR IMMEDIATE RELEASE Media Contact: Pamela Eisele Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Courtney Ronaldo (908) 740-6132 Merck Completes Acquisition of ArQule KENILWORTH, N. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. POSASR - - POSASR As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
Amended and Restated Certificate of Incorporation of ArQule, Inc., dated January 16, 2020. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARQULE, INC. FIRST: The name of the corporation is ArQule, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of its registered agent at such address is The Corporation Trust Company. THIR |
|
| January 16, 2020 |
Amended and Restated By-Laws of ArQule, Inc., dated January 16, 2020. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARQULE, INC. Article I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors (the “Board o |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 16, 2020 |
MRK / Merck & Co., Inc. SC TO-T/A - - SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 5 ARQULE, INC. (Name of Subject Company (Issuer)) Argon Merger Sub, Inc. a wholly-owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.01 per share |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS S-8 POS 1 forms8pos.htm S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. 333-19469 Registration No. 333-25369 Registration No. 333-25371 Registration No. 333-55705 Registration No. 333-82113 Registration No. 333-43044 Registration No. 333-43046 Registration No. 333-55502 Registration No. 333-68056 Registration No. 333-68058 Registration No. 333-1052 |
|
| January 16, 2020 |
ARQL / ArQule, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on January 16, 2020 Registration No. |
|
| January 10, 2020 |
ARQL / ArQule, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ArQule, Inc. (Name of Issuer) Common Stock, par value $.01 (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 9, 2020 |
ARQL / ArQule, Inc. / Bleichroeder Lp - ARQULE-13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ArQule, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 6, 2020 |
ARQL / ArQule, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A 1 tm201349d1sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of |
|
| January 6, 2020 |
MRK / Merck & Co., Inc. SC TO-T/A - - SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 4 ARQULE, INC. (Name of Subject Company (Issuer)) Argon Merger Sub, Inc. a wholly-owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.01 per share |
|
| January 3, 2020 |
MRK / Merck & Co., Inc. SC TO-T/A - - SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 3 ARQULE, INC. (Name of Subject Company (Issuer)) Argon Merger Sub, Inc. a wholly-owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.01 per share |
|
| January 3, 2020 |
ARQL / ArQule, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Numbe |
|
| January 2, 2020 |
MRK / Merck & Co., Inc. SC TO-T/A - - SC TO-T/A SC TO-T/A 1 nc10007326x1sctota.htm SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 ARQULE, INC. (Name of Subject Company (Issuer)) Argon Merger Sub, Inc. a wholly-owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offer |
|
| January 2, 2020 |
ARQL / ArQule, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Numbe |
|
| December 30, 2019 |
ARQL / ArQule, Inc. SC 14D9/A - - SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Numbe |
|
| December 30, 2019 |
MRK / Merck & Co., Inc. SC TO-T/A - - SC-TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 ARQULE, INC. (Name of Subject Company (Issuer)) Argon Merger Sub, Inc. a wholly-owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.01 per share |
|
| December 17, 2019 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ARQULE, INC. |
|
| December 17, 2019 |
NON-DISCLOSURE, INVENTIONS ASSIGNMENT, NON-COMPETITION AND NON-SOLICITATION AGREEMENT Exhibit (e)(36) NON-DISCLOSURE, INVENTIONS ASSIGNMENT, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Non-Disclosure, Inventions Assignment, Non-Competition and Non-Solicitation Agreement (this “Agreement”) is entered into as of the date set forth below (the “Effective Date”) between ArQule, Inc. |
|
| December 17, 2019 |
Exhibit 2.1 FIRST AMENDMENT TO AGREEMENT AND PLAN OF MERGER This First Amendment (this “Amendment”) is made and entered into as of December 17, 2019, by and among Merck Sharp & Dohme Corp., a New Jersey corporation (“Parent”), Argon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and ArQule, Inc., a Delaware corporation (the “Company” and, together |
|
| December 17, 2019 |
ARQL / ArQule, Inc. SC 14D9 - - SC 14D9 SC 14D9 1 tv534682-sc14d9.htm SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 04 |
|
| December 17, 2019 |
Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| December 17, 2019 |
Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of ArQule, Inc. |
|
| December 17, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 tm1926396d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2019 (December 17, 2019) ArQule, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21429 04-3221586 (State or othe |
|
| December 17, 2019 |
NON-DISCLOSURE, INVENTIONS ASSIGNMENT, NON-COMPETITION AND NON-SOLICITATION AGREEMENT Exhibit (e)(37) NON-DISCLOSURE, INVENTIONS ASSIGNMENT, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Non-Disclosure, Inventions Assignment, Non-Competition and Non-Solicitation Agreement (this “Agreement”) is entered into as of the date set forth below (the “Effective Date”) between ArQule, Inc. |
|
| December 17, 2019 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of ARQULE, INC. |
|
| December 17, 2019 |
Merck Begins Tender Offer to Acquire ArQule Exhibit (a)(1)(G) News Release Media Contacts: Pamela Eisele Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Ayn Wisler Courtney Ronaldo (917) 691-6218 (908) 740-6132 Merck Begins Tender Offer to Acquire ArQule KENILWORTH, N. |
|
| December 17, 2019 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ARQULE, INC. |
|
| December 17, 2019 |
MRK / Merck & Co., Inc. SC TO-T - - SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ARQULE, INC. (Name of Subject Company (Issuer)) Argon Merger Sub, Inc. a wholly-owned subsidiary of Merck Sharp & Dohme Corp. (Names of Filing Persons (Offerors)) Common Stock, par value $0.01 per share (Title of Class |
|
| December 17, 2019 |
EMPLOYEE NON-DISCLOSURE AND INVENTIONS AGREEMENT Exhibit (e)(35) EMPLOYEE NON-DISCLOSURE AND INVENTIONS AGREEMENT In consideration of my employment or continued employment by ArQule, Inc. |
|
| December 16, 2019 |
EX-99.3 3 nc10006926x1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01 per share, of ArQule, Inc., a Delaware |
|
| December 16, 2019 |
AMENDED AND RESTATED MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT Exhibit 99.2 AMENDED AND RESTATED MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Amended and Restated Mutual Confidential Disclosure Agreement (this "Agreement"), effective as of the date of last signature below (the "Effective Date"), is entered into by and between Merck Sharp & Dohme Corp., having an address of 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as "Me |
|
| December 16, 2019 |
ARQL / ArQule, Inc. / Merck & Co., Inc. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 ArQule, Inc. (Name of Subject Company — Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number of Class of Securities) Geralyn S. Ritter Senior Vice President and Corporate Secretary Merck & Co., Inc. 2000 Galloping Hill Road |
|
| December 10, 2019 |
ARQL / ArQule, Inc. SC14D9C - - SC14D9C SC14D9C 1 tm1924867d1sc14d9c.htm SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) |
|
| December 10, 2019 |
Exhibit 99.2 ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting - ARQ 531 demonstrates substantial anti-tumor activity and manageable safety profile - Eight of nine evaluable CLL patients initially dosed at ≥65 mg experienced a Partial Response (PR) - Five of five CLL patients that were evaluable at the |
|
| December 10, 2019 |
Exhibit 99.1 Letter to Partners Dear , I am writing to share some important news regarding ArQule. Today we announced that we have entered into an agreement to be acquired by Merck. A copy of the joint press release we issued is attached for your reference. Merck is a leading global biopharmaceutical company that has brought forward a wide range of therapies to address many of the world’s most cha |
|
| December 10, 2019 |
ArQule, Inc. (ARQ 531 Clinical Update from ASH) December 09, 2019 Exhibit 99.3 ArQule, Inc. (ARQ 531 Clinical Update from ASH) December 09, 2019 Corporate Speakers: · Marc Schegerin; ArQule, Inc.; CFO, Head of Strategy & Treasurer · Paolo Pucci; ArQule, Inc.; CEO & Director · Peter Lawrence; ArQule, Inc.; President, COO, General Counsel & Secretary · Brian Schwartz; ArQule, Inc.; Chief Medical Officer & Senior VP Participants: · Gregory Renza; RBC Capital Market |
|
| December 9, 2019 |
MRK / Merck & Co., Inc. SC TO-C - - SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ArQule, Inc. (Name of Subject Company — Issuer) ARGON MERGER SUB, INC. a wholly-owned subsidiary of MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Stock, par value $0.01 per share (Title of Class |
|
| December 9, 2019 |
Exhibit 99.8 Analyst and Investor Email SUBJECT: Merck to Acquire ArQule in Transaction Valued at Approximately $2.7 Billion , We’ve just announced that ArQule has entered into an agreement to be acquired by Merck in a transaction valued at approximately $2.7 billion. The joint press release we issued can be found here. Key highlights of the transaction include: · ArQule shareholders will receive |
|
| December 9, 2019 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 6, 2019 AMONG MERCK SHARP & DOHME CORP., ARGON MERGER SUB, INC. AND ARQULE, INC. Table of Contents Page ARTICLE 1 DEFINITIONS; INTERPRETATION 2 SECTION 1.1. Definitions 2 SECTION 1.2. Interpretation 13 ARTICLE 2 THE OFFER 13 SECTION 2.1. The Offer 13 SECTION 2.2. Company Action 15 ARTICLE 3 THE MERGER 16 SECTION 3.1. T |
|
| December 9, 2019 |
Exhibit 99.2 |
|
| December 9, 2019 |
8-K 1 tm1924665d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2019 (December 6, 2019) ArQule, Inc. (Exact name of registrant as specified in its charter) Delaware 000-21429 04-3221586 (State or other |
|
| December 9, 2019 |
Letter to Patient Advocacy Groups Exhibit 99.7 Letter to Patient Advocacy Groups Dear , I am writing to share some important news regarding ArQule. Today we announced that we have entered into an agreement to be acquired by Merck. A copy of the joint press release we issued is attached for your reference. Merck is a leading global biopharmaceutical company that has brought forward a wide range of therapies to address many of the w |
|
| December 9, 2019 |
Exhibit 99.2 News Release Merck Media: Pam Eisele Merck Investors: Peter Dannenbaum (267) 305-3558 Ayn Wisler (917) 691-6218 (908) 740-1037 Courtney Ronaldo (908) 740-6132 ArQule Media: Cait Williamson, Ph.D. ArQule Investors: Marc Schegerin, M.D. (646) 751-4366 (781) 994-0300 Merck to Acquire ArQule, Advancing Leadership in Oncology Acquisition Further Diversifies Merck’s Oncology Pipeline with E |
|
| December 9, 2019 |
Exhibit 99.1 FORM OF SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of December 6, 2019, is entered into by and among [●] (“Stockholder”), Merck Sharp & Dohme Corp., a New Jersey corporation (“Parent”) and Argon Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). WHEREAS, contemporaneously with the execution of this Agreement, Par |
|
| December 9, 2019 |
ArQule’s Transformative Agreement with Merck Exhibit 99.5 ArQule’s Transformative Agreement with Merck On December 9, 2019, ArQule announced that it has entered into a definitive agreement to be acquired by Merck. As part of Merck, with its vast capabilities and resources, we believe the potential of ArQule’s pipeline will be accelerated with the goal of bringing potentially transformative treatments to patients in desperate need. The transa |
|
| December 9, 2019 |
Letter to Key Opinion Leaders, Physicians and Investigators EX-99.6 7 tm1924751d1ex99-6.htm EXHIBIT 99.6 Exhibit 99.6 Letter to Key Opinion Leaders, Physicians and Investigators Dear , I am writing to share some important news regarding ArQule. Today we announced that we have entered into an agreement to be acquired by Merck. A copy of the joint press release we issued is attached for your reference. Merck is a leading global biopharmaceutical company that |
|
| December 9, 2019 |
Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Media: Pam Eisele Merck Investors: Peter Dannenbaum (267) 305-3558 Ayn Wisler (917) 691-6218 (908) 740-1037 Courtney Ronaldo (908) 740-6132 ArQule Media: Cait Williamson, Ph.D. ArQule Investors: Marc Schegerin, M.D. (646) 751-4366 (781) 994-0300 Merck to Acquire ArQule, Advancing Leadership in Oncology Acquisition Further Diversifies Merck’ |
|
| December 9, 2019 |
EX-99.4 5 tm1924751d1ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 |
|
| December 9, 2019 |
Second Amended and Restated By-Laws of ArQule, Inc., dated December 6, 2019, as amended. Exhibit 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF ARQULE, INC. December 6, 2019 Article I STOCKHOLDERS SECTION 1. Place of Meetings. All meetings of stockholders shall be held at the principal office of the corporation or at such other place as may be named in the notice. SECTION 2. Annual Meeting. The annual meeting of stockholders for the election of directors and the transaction of such other |
|
| December 9, 2019 |
Exhibit 99.1 News Release Merck Media: Pam Eisele Merck Investors: Peter Dannenbaum (267) 305-3558 Ayn Wisler (917) 691-6218 (908) 740-1037 Courtney Ronaldo (908) 740-6132 ArQule Media: Cait Williamson, Ph.D. ArQule Investors: Marc Schegerin, M.D. (646) 751-4366 (781) 994-0300 Merck to Acquire ArQule, Advancing Leadership in Oncology Acquisition Further Diversifies Merck’s Oncology Pipeline with E |
|
| December 9, 2019 |
EX-99.3 4 tm1924751d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 |
|
| December 9, 2019 |
ARQL / ArQule, Inc. SC14D9C - - SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 ArQule, Inc. (Name of Subject Company) ArQule, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number of Class of Secu |
|
| November 20, 2019 |
Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| October 30, 2019 |
ARQL / ArQule, Inc. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended September 30, 2019 Commission File No. |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| October 30, 2019 |
ArQule Reports Third Quarter 2019 Financial Results Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 ArQule Reports Third Quarter 2019 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, October 30, 2019 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2019. For the quarter ended September 30, 2019, the Company reported a net loss of $10.7 million, or $0.09 per basic share, compared with net loss of $5.6 millio |
|
| September 19, 2019 |
EX-99.2 2 tv529773ex-2.htm EXHIBIT 2 Exhibit 2 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsib |
|
| September 19, 2019 |
ARQL / ArQule, Inc. / Pontifax Management 4 G.p. (2015) Ltd. - SC 13D/A Activist Investment SC 13D/A 1 tv529773sc13d-a.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ArQule, Inc. (Name of Issuer) Common Stock Par Value $0.01 Per Share (Title of Class of Securities) 04269E107 (CUSIP Number) Asaf Shinar Pontifax 14 Shenkar Street Herzliya Pituach 46140, Israel 972-9-9725617 (Name |
|
| September 19, 2019 |
EX-99.3 3 tv529773ex-3.htm EXHIBIT 3 Exhibit 3 STRATEGIC ALLIANCE AGREEMENT This Strategic Alliance Agreement (the “Agreement”) is made as of August 9, 2018 (the “Effective Date”), by and between Pontifax IV GP LP (“GP4”), Pontifax V GP LP (“GP5”) and Pontifax Late Stage GP Ltd (“LS GP”). 1. All capitalized terms used and not defined herein shall have the meaning ascribed thereto in the Limited Pa |
|
| September 6, 2019 |
ARQL / ArQule, Inc. / Bleichroeder Lp - ARQULE-13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) (RULE 13d-102) Information to be included in statements filed pursuant to Rule 13d-1 (b) (c) and (d) and Amendments thereto filed pursuant to Rule 13d-2 (b). ArQule, Inc. (Name of Issuer) Common shares (Title of Class of Securities) 04269E107 (CUSIP/SED |
|
| September 5, 2019 |
ARQL / ArQule, Inc. / Bleichroeder Lp - ARQULE-SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. ) (RULE 13d-102) Information to be included in statements filed pursuant to Rule 13d-1 (b) (c) and (d) and Amendments thereto filed pursuant to Rule 13d-2 (b). ArQule, Inc. (Name of Issuer) Common shares (Title of Class of Securities) 04269E107 (CUSIP/SEDOL |
|
| August 7, 2019 |
ArQule Reports Second Quarter 2019 Financial Results Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 ArQule Reports Second Quarter 2019 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, August 7, 2019 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2019. For the quarter ended June 30, 2019, the Company reported a net loss of $9.1 million, or $0.08 per basic share, compared with net income of $5.2 million, o |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 tv5268898k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) ( |
|
| August 7, 2019 |
ARQL / ArQule, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 tv52631110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended June 30, 2019 Commission File No. 000-21429 ArQule, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3221586 (State of Incorporation) (I.R.S. Employer Ide |
|
| July 25, 2019 |
ARQL / ArQule, Inc. CORRESP - - July 25, 2019 Securities and Exchange Commission Division of Corporation Finance Office of Healthcare and Insurance 100 F Street, N. |
|
| June 25, 2019 |
ArQule Announces Commencement of Proposed Public Offering of Common Stock Exhibit 99.1 ArQule Announces Commencement of Proposed Public Offering of Common Stock Burlington, MA, June 24, 2019 - ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to pur |
|
| June 25, 2019 |
1.1—Underwriting Agreement dated June 24, 2019 Exhibit 1.1 Execution Version ArQule, Inc. (a Delaware corporation) 9,250,000 Shares of Common Stock UNDERWRITING AGREEMENT June 24, 2019 SVB Leerink LLC RBC Capital Markets, LLC as Representatives of the several Underwriters c/o SVB Leerink LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o RBC Capital Markets, LLC 200 Vesey Street New York, New York 10281 Ladies and Gentlemen: Ar |
|
| June 25, 2019 |
ArQule Announces Pricing of $90 Million Public Offering of Common Stock Exhibit 99.2 ArQule Announces Pricing of $90 Million Public Offering of Common Stock Burlington, MA, June 25, 2019 - ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.75 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1,387,500 shares of its |
|
| June 25, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report: June 24, 2019 (Date of earliest event reported) ArQule, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-21429 04-3221586 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| June 25, 2019 |
CALCULATION OF REGISTRATION FEE TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-232306 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Maximum Offering Price Per Share(1) Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.01 per share 10,637,500 $ 9.75 $ 103,715,625 $ 12,570.33 (1) Includes 1,387,500 |
|
| June 24, 2019 |
SUBJECT TO COMPLETION, DATED JUNE 24, 2019 424B5 1 tv524099424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-232306 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer |
|
| June 24, 2019 |
Form of Indenture (filed herewith) EXHIBIT 4.1 ARQULE, INC. ——————————— INDENTURE Dated as of ——————————— [TRUSTEE] Trustee TABLE OF CONTENTS Page Article I. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 Article II. THE SECURITIES Section 2.1 Issuable in Series 6 Section 2.2 Esta |
|
| June 24, 2019 |
ARQL / ArQule, Inc. S-3ASR - - S-3ASR As Filed with the Securities and Exchange Commission on June 24, 2019 Registration No. |
|
| June 14, 2019 |
ARQL / ArQule, Inc. CORRESP - - FOIA CONFIDENTIALTREATMENT REQUEST UNDER 17 C.F.R. §200.83 CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY ARQULE, INC. WITH RESPECT TO THE OMITTED PORTIONS. OMITTED INFORMATION HAS BEEN REPLACED IN THIS LETTER AS FILED VIA EDGAR WITH A PLACEHOLDER IDENTIFIED BY THE M |
|
| May 14, 2019 |
8-K 1 tv5215998k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) (Co |
|
| May 13, 2019 |
ARQL / ArQule, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARQULE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 04269E107 (CUSIP Number) MAY 1, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| May 1, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Empl |
|
| May 1, 2019 |
ArQule Reports First Quarter 2019 Financial Results Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 ArQule Reports First Quarter 2019 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, May 1, 2019 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter, 2019. For the quarter ended March 31, 2019, the Company reported a net loss of $10,267,000, or $0.09 per share, compared with net loss of $6,532,000, or $0.07 per share |
|
| May 1, 2019 |
EX-10.4 5 tv519628ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fifth Amendment to Employment Agreement (“Fifth Amendment”), effective as of March 29, 2019 (the “Effective Date”) is entered into by and between ArQule, Inc., a Delaware corporation (the “Company”) with its principal offices at One Wall Street, Burlington, Massachusetts 01803, and Brian Schwartz (“ |
|
| May 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended March 31, 2019 Commission File No. |
|
| May 1, 2019 |
Separation of Employment Agreement, dated March 13, 2019, between the Company and Robert Weiskopf. Exhibit 10.1 March 13, 2019 Robert J. Weiskopf Dear Rob: The purpose of this letter agreement (the “Agreement”) is to confirm the terms regarding your separation of employment with ArQule, Inc.1 (“ArQule” or the “Company”). As more fully set forth below, ArQule desires to provide you with Severance Pay and Severance Benefits described herein in exchange for certain agreements by you. This Agreemen |
|
| May 1, 2019 |
EX-10.2 3 tv519628ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fifth Amendment to Employment Agreement (“Fifth Amendment”), effective as of March 29, 2019 (the “Effective Date”) is entered into by and between ArQule, Inc., a Delaware corporation (the “Company”) with its principal offices at One Wall Street, Burlington, Massachusetts 01803, and Paolo Pucci (“Exe |
|
| May 1, 2019 |
Exhibit 10.3 SIXTH AMENDMENT TO EMPLOYMENT AGREEMENT This Sixth Amendment to Employment Agreement (“Sixth Amendment”), effective as of March 29, 2019 (the “Effective Date”) is entered into by and between ArQule, Inc., a Delaware corporation (the “Company”) with its principal offices at One Wall Street, Burlington, Massachusetts 01803, and Peter Lawrence (“Executive”). The purpose of this Sixth Ame |
|
| May 1, 2019 |
Letter Agreement, dated April 11, 2019, by and between the Company and Marc Schegerin. EX-10.5 6 tv519628ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 April 11, 2019 Dear Marc, In connection with your recent promotion, I am pleased to offer you the benefits outlined herein in addition to those contained in your original Offer Letter with ArQule, Inc. (the “Company”), dated March 22, 2018 (the “Offer Letter”). Your new title shall be Senior Vice President, Chief Financial Officer and Treasure |
|
| April 15, 2019 |
8-K 1 tv5188778k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) ( |
|
| March 28, 2019 |
definitive proxy statement on Schedule 14A, filed with the SEC on March 28, 2019 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 18, 2019 |
ARQL / ArQule, Inc. / 1Globe Capital LLC - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur |
|
| March 15, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 tv5163118-k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) |
|
| March 15, 2019 |
ArQule Announces Management Team Changes EX-99.1 2 tv516311ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release: ArQule Announces Management Team Changes Burlington, MA, March 15, 2019 - ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year. In conjunction with Mr. Weiskopf’s departure, ArQule is naming Ma |
|
| March 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2019 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incor |
|
| March 7, 2019 |
EX-99.1 2 tv515573ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ArQule Reports Fourth Quarter and Full Year 2018 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, March 7, 2019 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the fourth quarter and full year of 2018. For the quarter ended December 31, 2018, the Company reported a net loss of $8,487,000 |
|
| March 7, 2019 |
Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 7, 2019 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 COMMISSION FILE NUMBER: 000-21429 ARQULE, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATIO |
|
| March 7, 2019 |
Exhibit 10.24 DATE OF PROSPECTUS: NOVEMBER 1, 2018 ARQULE, INC. 2014 EQUITY INCENTIVES PLAN (“Plan”) Incentive Stock Option Terms and Conditions This document constitutes part of a prospectus covering securities that may be issued under the Plan and registered under the Securities Act of 1933, as amended. Neither the Securities and Exchange Commission nor any state securities commission has approv |
|
| March 7, 2019 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 06:08 PM 01/24/2011 FILED 06:08 PM 01/24/2011 SRV 110074132 - 2364850 FILE RESTATED CERTIFICATE OF INCORPORATION OF ARQULE, INC. I, Peter S. Lawrence, President and Chief Operating Officer of ArQule, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delawa |
|
| March 7, 2019 |
EX-10.25 4 tv514851ex10-25.htm EXHIBIT 10.25 Exhibit 10.25 DATE OF PROSPECTUS: NOVEMBER 1, 2018 ARQULE, INC. 2014 EQUITY INCENTIVES PLAN (“Plan”) Non-Qualified Stock Option Terms and Conditions This document constitutes part of a prospectus covering securities that may be issued under the Plan and registered under the Securities Act of 1933, as amended. Neither the Securities and Exchange Commissi |
|
| February 14, 2019 |
SC 13G/A 1 sc13ga807422arq02142019.htm AMENDMENT NO. 8 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 8)1 ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per |
|
| February 14, 2019 |
ARQL / ArQule, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tv513713sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ArQule, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| February 11, 2019 |
ARQL / ArQule, Inc. / VANGUARD GROUP INC Passive Investment SC 13G 1 arquleinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: ArQule Inc Title of Class of Securities: Common Stock CUSIP Number: 04269E107 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designate the rule pursuant to which this Sched |
|
| February 4, 2019 |
ARQL / ArQule, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ARQULE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 04269E107 (CUSIP Number) DECEMBER 31, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuan |
|
| November 29, 2018 |
S-8 1 tv507995s-8.htm FORM S-8 neAs filed with the Securities and Exchange Commission on November 29, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARQULE, INC. (Exact name of registrant as specified in its charter) Delaware 04-3221586 (State or other jurisdiction of incorporation |
|
| November 29, 2018 |
As filed with the Securities and Exchange Commission on November 29, 2018 Registration No. |
|
| October 31, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2018 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of in |
|
| October 31, 2018 |
ArQule Reports Third Quarter 2018 Financial Results Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 FOR IMMEDIATE RELEASE: ArQule Reports Third Quarter 2018 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, October 31, 2018 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2018. For the quarter ended September 30, 2018, the Company reported a net loss of $5,619,000 or $0.05 per share, compared with a net loss |
|
| October 31, 2018 |
ARQL / ArQule, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 tv50544510q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended September 30, 2018 Commission File No. 000-21429 ArQule, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3221586 (State of Incorporation) (I.R.S. Employe |
|
| August 1, 2018 |
ArQule Reports Second Quarter 2018 Financial Results Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 Contact: Marc Schegerin, MD Senior Vice President Strategy, Finance & Communications [email protected] www.ArQule.com FOR IMMEDIATE RELEASE: ArQule Reports Second Quarter 2018 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, August 1, 2018 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2018. For the quarter |
|
| August 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2018 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of inco |
|
| August 1, 2018 |
Exhibit 10.1 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions. LICENSE AGREEMENT by Arqule, inc. and Basilea Pharmaceutica International Limited Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions. Execution Version Licence Agreement |
|
| August 1, 2018 |
ARQL / ArQule, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 tv49895010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended June 30, 2018 Commission File No. 000-21429 ArQule, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3221586 (State of Incorporation) (I.R.S. Employer Ide |
|
| July 13, 2018 |
ArQule Announces Commencement of Proposed Public Offering of Common Stock Exhibit 99.1 ArQule Announces Commencement of Proposed Public Offering of Common Stock Burlington, MA, July 10, 2018 - ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the offering, ArQule expects to grant the underwriters a 30-day option to pur |
|
| July 13, 2018 |
Exhibit 1.1 ArQule, Inc. (a Delaware corporation) 11,000,000 Shares of Common Stock UNDERWRITING AGREEMENT July 10, 2018 Leerink Partners LLC as Representative of the several Underwriters c/o Leerink Partners LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: ArQule, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Partners LLC (“L |
|
| July 13, 2018 |
ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock Exhibit 99.2 ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock Burlington, MA, July 11, 2018 - ArQule, Inc. (Nasdaq: ARQL) today announced the pricing of an underwritten public offering of 11 million shares of its common stock at a price to the public of $5.50 per share. ArQule has granted the underwriters a 30-day option to purchase up to an additional 1.65 million shares |
|
| July 13, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report: July 10, 2018 (Date of earliest event reported) ArQule, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-21429 04-3221586 (State or Other Jurisdiction of Incorporation or Organization) (Com |
|
| July 12, 2018 |
11,000,000 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-213456 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2016) 11,000,000 Shares Common Stock We are offering 11,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “ARQL.” On July 10, 2018, the last reported sale price of our common stock on The Nasdaq Global Marke |
|
| July 10, 2018 |
SUBJECT TO COMPLETION, DATED JULY 10, 2018 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-213456 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell thes |
|
| June 28, 2018 |
Exhibit 2 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). |
|
| June 28, 2018 |
ARQL / ArQule, Inc. / Pontifax Management 4 G.p. (2015) Ltd. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. n/a)* ArQule, Inc. (Name of Issuer) Common Stock Par Value $0.01 Per Share (Title of Class of Securities) 04269E107 (CUSIP Number) Asaf Shinar Pontifax 14 Shenkar Street Herzliya Pituach 46140, Israel 972-9-9725617 (Name, Address and Telephone Number of Pers |
|
| June 18, 2018 |
ARQL / ArQule, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARQULE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 04269E107 (CUSIP Number) JUNE 6, 2018 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| June 1, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 7)1 ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number) May 30, 2018 |
|
| May 29, 2018 |
May 29, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Mail Stop 4546 Attn: Mary Beth Breslin or Abigail Jacobs Re: ArQule, Inc. Registration Statement on Form S-3 File No. 333-225008 Request for Acceleration Ladies and Gentlemen: ArQule, Inc. hereby requests that the Securities and Exchange Commission accelerate the |
|
| May 17, 2018 |
As Filed with the Securities and Exchange Commission on May 17, 2018 Registration No. |
|
| May 10, 2018 |
ARQULE, INC. 2018 Annual Meeting Report of Matters Voted Upon by Stockholders EX-99.1 2 tv493640ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ARQULE, INC. 2018 Annual Meeting Report of Matters Voted Upon by Stockholders 1. The 2018 Annual Meeting of Stockholders of ArQule, Inc. (the “Annual Meeting”) was held at the Boston Burlington Marriott, One Mall Road, Burlington, Massachusetts on May 8, 2018 commencing at 10:00 a.m. pursuant to notice properly given. 2. At the close of busine |
|
| May 10, 2018 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K 1 tv4936408k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of incorporation) (Com |
|
| May 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2018 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorpo |
|
| May 7, 2018 |
ARQULE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 Contact: Paolo Pucci Chief Executive Officer (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ARQULE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Burlington, MA, May 7, 2018– ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2018. For the quarter ended March 31, 2018, the Company reported a ne |
|
| May 7, 2018 |
ARQL / ArQule, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended March 31, 2018 Commission File No. |
|
| April 17, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 16, 2018 ARQULE, INC. |
|
| April 17, 2018 |
EX-99.1 2 tv491169ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Paolo Pucci Chief Executive Officer (781) 994-0300 www.ArQule.com ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World excluding Greater China ArQule eligible to receive up to $336 million including upfront, regulatory and commercial milestone payments ArQule to host investo |
|
| March 29, 2018 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 8, 2018 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 5, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 5, 2018 ARQULE, INC. |
|
| March 5, 2018 |
EX-99.1 2 tv487649ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Dawn Schottlandt,Vice President, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ArQule Reports Fourth Quarter and Full Year 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, March 5, 2018 – ArQule, Inc. (NASDAQ: ARQL) today announced its financial resu |
|
| March 5, 2018 |
Exhibit 10.35 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions. EXECUTION VERSION LICENSE AGREEMENT dated FEBRUARY 2, 2018 among ARQULE, INC., SINOVANT SCIENCES LTD and ROIVANT SCIENCES LTD. Allen & Overy Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple ast |
|
| March 5, 2018 |
ARQL / ArQule, Inc. FORM 10-K (Annual Report) 10-K 1 tv487013-10k.htm FORM 10-K TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 COMMISSION FILE NUMBER: 000-21429 ARQULE, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE (STATE OR OTHER JURISDICTI |
|
| February 22, 2018 |
8-K 1 tv4865838k.htm 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2018 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Em |
|
| February 22, 2018 |
Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of February 16, 2018, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), the |
|
| February 22, 2018 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| February 14, 2018 |
ARQL / ArQule, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ArQule, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 7, 2018 |
Exhibit 99.1 Contact: Dawn Schottlandt Vice President, Investor Relations/Corp. Communications (781) 994-0300 www.ArQule.com Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China Collaboration will expand the clinical development of derazantinib HONG KONG and BURLINGTON, Mass. February 7, 2018 ? (Business Wire) ? Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today a |
|
| February 7, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 2, 2018 ARQULE, INC. |
|
| December 6, 2017 |
As Filed with the Securities and Exchange Commission on December 6, 2017 Registration No. |
|
| November 9, 2017 |
ArQule Reports Third Quarter 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET EX-99.1 2 tv479029ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contacts: Dawn Schottlandt Vice President, Investor Relations/ Corp. Communications (781) 994-0300 www.ArQule.com FOR IMMEDIATE RELEASE: ArQule Reports Third Quarter 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, November 9, 2017 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the |
|
| November 9, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of in |
|
| November 9, 2017 |
EX-10.3 3 tv478509ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions. Scope of Work #1 This Scope of Work (this “Scope of Work” or “SOW”) is incorporated into the Master Services Agreement dated July 20, 2017 by and between ArQule and ARUP (for the purposes of this Scope of Work, |
|
| November 9, 2017 |
Exhibit 10.2 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions. execution copy MASTER SERVICES AGREEMENT This Master Services Agreement (this “Agreement”) is entered into as of July 20, 2017 (the “Effective Date”) by and between ArQule, Inc., a Delaware corporation having a place of business at One Wall Street, Bur |
|
| November 9, 2017 |
EX-10.4 4 tv478509ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. ***Triple asterisks denote omissions. Scope of Work #2 This Scope of Work is incorporated into the Master Services Agreement dated July 20, 2017 by and between ArQule and ARUP (for the purposes of this Scope of Work, the “Agreement”). This Scope of |
|
| November 9, 2017 |
ARQL / ArQule, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 tv47850910q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended September 30, 2017 Commission File No. 000-21429 ArQule, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3221586 (State of Incorporation) (I.R.S. Employe |
|
| November 8, 2017 |
Exhibit 99.1 Contact: Dawn Schottlandt Vice President, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ArQule Announces $9.5 Million Private Placement of Preferred Stock The Pontifax Group led this financing with additional participation from an Israeli-based healthcare equity fund Ran Nussbaum, Managing Partner and co-founder of The Pontifax Group, jo |
|
| November 8, 2017 |
Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF Series A Preferred Stock of ARQULE, INC. ArQule, Inc., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 151 of the Delaware General Corporation Law, does hereby certify that the following resolution was duly adopted by the Board of Directors of the Corporation on November 3, 2017: RESOLVED, that pursuant to the auth |
|
| November 8, 2017 |
Exhibit 4.1 SERIES A PREFERRED STOCK PURCHASE WARRANT ARQULE, INC. Warrant Shares: THIS SERIES A PREFERRED STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after November 7, 2017 (the ?Initial Exercise Date?) and |
|
| November 8, 2017 |
Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 5, 2017, between ArQule, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions set forth in this Agreement, the |
|
| November 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of in |
|
| October 20, 2017 |
ARQL / ArQule, Inc. / Biotechnology Value Fund L P - SCHEDULE 13G AMENDMENT NO. 6 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 6)1 ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number) October 20, |
|
| October 16, 2017 |
EX-10.1 3 tv476956ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October , 2017, between ArQule, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for |
|
| October 16, 2017 |
Exhibit 99.1 Contact: Dawn Schottlandt Vice President, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ArQule Announces $15.7 Million Private Placement of Common Stock Company also raises approximately $4M through unrelated business development activities and other sources during September-October Burlington, MA, October 16, 2017 ? ArQule, Inc. (NASDAQ |
|
| October 16, 2017 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ARQULE, INC. Warrant Shares: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October [?], 2017 (the ?Initial Exercise Date?) and on or prior to the clos |
|
| October 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of in |
|
| October 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number) October 11, |
|
| September 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 27, 2017 ARQULE, INC. |
|
| September 29, 2017 |
EX-99.1 2 v476237ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NOTICE OF RATIFICATION OF POTENTIALLY DEFECTIVE CORPORATE ACTS BY THE BOARD OF DIRECTORS OF ARQULE, INC. (Pursuant to Section 204(g) of the Delaware General Corporation Law) Notice is hereby given, pursuant to Section 204 (“Section 204”) of the Delaware General Corporation Law (the “DGCL”), that on September 19, 2017, the Board of Directors of |
|
| August 4, 2017 |
ArQule Reports Second Quarter 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET EX-99.1 2 t1700479ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Dawn Schottlandt Vice President, Investor Relations & Corp. Communications (781) 994-0300 www.ArQule.com FOR IMMEDIATE RELEASE: ArQule Reports Second Quarter 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, August 4, 2017 – ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the |
|
| August 4, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of inco |
|
| August 4, 2017 |
ARQL / ArQule, Inc. FORM 10-Q (Quarterly Report) 10-Q 1 t170046010q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended June 30, 2017 Commission File No. 000-21429 ArQule, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3221586 (State of Incorporation) (I.R.S. Employer Ide |
|
| July 26, 2017 |
Entry into a Material Definitive Agreement 8-K 1 t17004618k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Num |
|
| May 24, 2017 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorp |
|
| May 24, 2017 |
ARQULE, INC. 2017 Annual Meeting Report of Matters Voted Upon by Stockholders EX-99.1 2 t1700356ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ARQULE, INC. 2017 Annual Meeting Report of Matters Voted Upon by Stockholders 1. The 2017 Annual Meeting of Stockholders of ArQule, Inc. (the “Annual Meeting”) was held at the Boston Burlington Marriott, One Mall Road, Burlington, Massachusetts on May 23, 2017 commencing at 10:00 a.m. pursuant to notice properly given. 2. At the close of busin |
|
| May 3, 2017 |
ArQule FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended March 31, 2017 Commission File No. |
|
| May 3, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incorpo |
|
| May 3, 2017 |
ARQULE REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 Contact: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ARQULE REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Burlington, MA, May 3, 2017 ? ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter of 2017. For the quarter ended Marc |
|
| April 13, 2017 |
ArQule DEFINITIVE PROXY STATEMENT t1700124def14a - none - 4.9314931s TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Com |
|
| April 11, 2017 |
Exhibit 99.1 Contacts: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com For Immediate Release: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 Plan to initiate a phase 1 trial by Q3 of 2017 Burlington, MA, April 11, 2017 - ArQule, Inc. (Nasdaq: ARQL) today announced |
|
| April 11, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of inco |
|
| April 10, 2017 |
8-K 1 t17002208k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 4, 2017 ARQULE, INC. (Exact name of registrant as specified in its charter) Delaware 000-21429 04-3221586 (State or other jurisdiction of (Commission |
|
| April 10, 2017 |
Exhibit 10.4 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fourth Amendment to Employment Agreement (?Fourth Amendment?), effective as of April 4, 2017 (the ?Effective Date?) is entered into by and between ArQule, Inc., a Delaware corporation (the ?Company?) with its principal offices at One Wall Street, Burlington, Massachusetts 01803, and Brian Schwartz (?Executive?). The purpose of this Fourth |
|
| April 10, 2017 |
Exhibit 10.1 ARQULE, INC. 2014 EQUITY INCENTIVES PLAN PERFORMANCE STOCK OPTION AGREEMENT THIS PERFORMANCE STOCK OPTION AGREEMENT (the ?Option Agreement?) is dated as of April 5, 2017 (the ?Grant Date?) by and between ArQule, Inc., a Delaware Company (the ?Company?), and (the ?Participant?). Capitalized terms used herein and not otherwise defined shall have the meaning assigned to such terms in the |
|
| April 10, 2017 |
Exhibit 10.2 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fourth Amendment to Employment Agreement (?Fourth Amendment?), effective as of April 4, 2017 (the ?Effective Date?) is entered into by and between ArQule, Inc., a Delaware corporation (the ?Company?) with its principal offices at One Wall Street, Burlington, Massachusetts 01803, and Paolo Pucci (?Executive?). The purpose of this Fourth Ame |
|
| April 10, 2017 |
EX-10.3 4 t1700220ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fifth Amendment to Employment Agreement (“Fifth Amendment”), effective as of April 4, 2017 (the “Effective Date”) is entered into by and between ArQule, Inc., a Delaware corporation (the “Company”) with its principal offices at One Wall Street, Burlington, Massachusetts 01803, and Peter Lawrence (“E |
|
| March 27, 2017 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of inco |
|
| March 27, 2017 |
Exhibit 99.1 Contact: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan Burlington, MA, March 27, 2017 ? ArQule, Inc. (Nasdaq: ARQL) today reported that its partner, Kyowa Hakko Kirin, announced top-line results of |
|
| March 9, 2017 |
ArQule FORM 10-K (Annual Report) t1700123-10k - none - 8.30083s TABLE OF CONTENTS ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 COMMISSION FILE NUMBER: 000-21429 ARQULE, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) ? DELAWARE (STATE OR OTHER JURIS |
|
| March 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of incor |
|
| March 7, 2017 |
Exhibit 99.1 Contact: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results Conference call scheduled today at 9:00 a.m. ET Burlington, MA, March 7, 2017 ? ArQule, Inc. (NASDAQ: ARQL) today announced its financial results for the fourth quarter and full year of |
|
| February 17, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 t17001208k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File |
|
| February 17, 2017 |
Exhibit 99.1 Press Release Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma ? ArQule to host investor conference call on February 17, 2017 at 8:30 A.M. ET Burlington, MA, Tokyo, Japan, Munich Germany and Parsippany, NJ ? February 17, 2017 ? ArQule, Inc. (Nasdaq: ARQL) and Daiichi S |
|
| February 15, 2017 |
ARQL / ArQule, Inc. / 1Globe Capital LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ArQule Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 ArQule, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, |
|
| February 14, 2017 |
ARQL / ArQule, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ArQule, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 04269E107 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 10, 2017 |
EX-10.1 4 t1700016ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of January 6, 2017 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virgi |
|
| January 10, 2017 |
ArQule FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2017 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of inc |
|
| January 10, 2017 |
Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| January 10, 2017 |
EX-4.1 2 t1700016ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINI |
|
| November 7, 2016 |
ArQule FORM 10-Q (Quarterly Report) 10-Q 1 t160069810q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended September 30, 2016 Commission File No. 000-21429 ArQule, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 04-3221586 (State of Incorporation) (I.R.S. Employe |
|
| November 7, 2016 |
ARQULE REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 Contact: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ARQULE REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Burlington, MA, November 7, 2016 ? ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2016. For the quarter ended |
|
| November 7, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 t16007128k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2016 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File |
|
| October 26, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 25, 2016 ARQULE, INC. |
|
| October 26, 2016 |
Exhibit 1.1 ArQule, Inc. Common Stock ($0.01 par value per share) Capital on Demand? Sales Agreement JonesTrading Institutional Services LLC 780 Third Avenue New York, NY 10017 October 25, 2016 Ladies and Gentlemen: ARQULE, INC. a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with JONESTRADING INSTITUTIONAL SERVICES LLC (the ?Agent?), as follows: 1. Issuance and S |
|
| October 26, 2016 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-213456 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED OCTOBER 5, 2016) $30,000,000 COMMON STOCK We have entered into a Capital on Demand? Sales Agreement, or sales agreement, with JonesTrading Institutional Services LLC (?JonesTrading?) relating to the sale of shares of our common stock offered by this prospectus supplement and the accompanying pro |
|
| October 3, 2016 |
October 3, 2016 VIA EDGAR Suzanne Hayes, Assistant Director Office of Healthcare and Insurance Division of Corporation Finance Mail Stop 4546 United States Securities and Exchange Commission 100 F Street, N. |
|
| September 23, 2016 |
ArQule FORM S-3 (AMENDMENT NO. 1) S-3/A 1 t1600598s3a.htm FORM S-3 (AMENDMENT NO. 1) As Filed with the Securities and Exchange Commission on September 23 , 2016 Registration No. 333- 213456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARQULE, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or o |
|
| September 23, 2016 |
Richard E. Baltz +1 202.942.5000 +1 202.942.5999 Fax 601 Massachusetts Ave., NW Washington, DC 20001-3743 September 23, 2016 Re: ArQule, Inc. Registration Statement on Form S-3 File No. 333-213456 Dear Ms. Hayes: On behalf of ArQule, Inc. (the ?Company?), we are writing in response to the comment letter from the Staff dated September 15, 2016 with respect to the above referenced registration state |
|
| September 2, 2016 |
Exhibit 4.5 ARQULE, INC. Issuer and [TRUSTEE] Trustee Indenture Dated as of SUBORDINATED DEBT SECURITIES ARQULE, INC. CERTAIN SECTIONS OF THIS INDENTURE RELATING TO SECTIONS 310 THROUGH 318, INCLUSIVE, OF THE TRUST INDENTURE ACT OF 1939: Trust Indenture Act Section Indenture Section ?310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (b) 608; 610 ?311(a) 613 (b) 613 ?312(a) 701; |
|
| September 2, 2016 |
EX-4.3 2 t1600559ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 ARQULE, INC. Issuer and [TRUSTEE] Trustee Indenture Dated as of SENIOR DEBT SECURITIES ARQULE, INC. CERTAIN SECTIONS OF THIS INDENTURE RELATING TO SECTIONS 310 THROUGH 318, INCLUSIVE, OF THE TRUST INDENTURE ACT OF 1939: Trust Indenture Act Section Indenture Section §310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (b) 608; 610 |
|
| September 2, 2016 |
S-3 1 t1600559s3.htm FORM S-3 As Filed with the Securities and Exchange Commission on September 2, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARQULE, INC. (Exact name of registrant as specified in its charter) DELAWARE (State or other jurisdiction of incorporation or organizatio |
|
| August 3, 2016 |
ArQule FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarter Ended June 30, 2016 Commission File No. |
|
| August 3, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2016 ARQULE, INC. (Exact Name of Issuer as Specified in Charter) Delaware 000-21429 04-3221586 (State or other jurisdiction (Commission File Number) (I.R.S. Employer of inco |
|
| August 3, 2016 |
ARQULE REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Exhibit 99.1 Contact: Dawn Schottlandt Sr. Director, Investor Relations/ Corp. Communications (781) 994-0300 www.arqule.com FOR IMMEDIATE RELEASE: ARQULE REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS Conference call scheduled today at 9:00 a.m. ET Burlington, MA, August 3, 2016 ? ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2016. For the quarter ended |
